SOURCE: Mazal Plant Pharmaceuticals, Inc.

September 20, 2006 17:00 ET

Dr. Robert Siegel Appointed as Scientific Director

NEW YORK, NY -- (MARKET WIRE) -- September 20, 2006 -- Mazal Plant Pharmaceuticals, Inc. (PINKSHEETS: MZPP) (FRANKFURT: M9J) announced today the appointment of Dr. Robert Siegel as its Scientific Director.

Dr. Siegel is currently a Clinical Associate Professor at Mount Sinai School of Medicine in New York City, and Director of the Critical Care Patient Center at the James J. Peters Veterans Affairs Medical Center in the Bronx, NY. Dr. Siegel is board certified in internal medicine, Pulmonary Medicine and Critical Care Medicine. Dr. Siegel's efforts have been supported by several industry grants and he has served as Principal Investigator in many clinical trials of infectious diseases. He has published numerous papers and lectures extensively on the subjects of infection, infectious disease and bacterial resistance formation.

Dr. Mechael Kanovsky, President of Mazal Plant Pharmaceuticals, Inc., said, "We're very fortunate to add Dr. Siegel to the Mazal team. His medical knowledge and his experience in the pharmaceutical industry will be a valuable asset to our company."

Dr. Siegel added, "I am excited to be a part of the Mazal team and am looking forward to helping in the upcoming clinical trials and finding Pharmaceutical Industry partners to further our goals of making naturally derived pharmaceutically active drugs become mainstream products."

About Mazal Plant Pharmaceuticals, Inc.

Mazal Plant Pharmaceuticals, Inc. is an early-stage whole plant pharmaceutical development company whose mission is to develop treatments for chronic diseases from combinations of whole plants and to build shareholder value through negotiated relationships with strategic partners to fund commercialization and marketing of these treatments on a stand-alone or combination basis.

Additional information on Mazal Plant Pharmaceuticals, Inc. may be found at:

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Mazal Plant Pharmaceuticals, Inc. to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Mazal Plant Pharmaceuticals, Inc.'s subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Mazal Plant Pharmaceuticals assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact Information

  • Contact:
    LC group
    Rick Lutz
    (404) 261-1196